Journal
LEUKEMIA & LYMPHOMA
Volume 56, Issue 4, Pages 858-865Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/10428194.2014.938328
Keywords
Hedgehog signaling pathway; hematological malignancy; targeted therapy; smoothened inhibitor
Categories
Funding
- National Natural Science Foundation [81270598]
- Natural Science Foundation of Shandong Province [Y2007C053, 2009ZRB14176, ZR2012HZ003]
- Technology Development Projects of Shandong Province [2007GG10, 2010GSF10250]
- Program of Shandong Medical Leading Talent
- Taishan Scholar Foundation of Shandong Province
Ask authors/readers for more resources
The hedgehog (Hh) signaling pathway is well established as being evolutionarily conserved across vertebrates, and is involved in organogenesis, hematopoiesis, embryogenesis and homeostasis of adult tissues. At a microscopic level, the Hh signaling pathway controls the proliferation, apoptosis, cell-cycle and differentiation programs of stem and progenitor cells. Increasing evidence suggests that aberrant activation of the Hh signaling pathway is related to neoplasm, including solid tumors and hematologic malignancies. Currently the Hh signaling pathway has become one of the most studied potential therapeutic targets in hematological malignancies. In this review, we focus on findings related to Hh signaling in the initiation, maintenance, progression and chemoresistance of hematological malignancies, looking forward to better targeted treatment strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available